1. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne Amler, Maria C. Sauerland, Dennis Görlich, Stephanie Schneider, Nikola P. Konstandin, Annika Dufour, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Luise Hartmann, Philipp A. Greif, Michael Fiegl, Marion Subklewe, Stefan K. Bohlander, Utz Krug, Andreas Faldum, Wolfgang E. Berdel, Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann, Jan Braess, and Karsten Spiekermann Blood Volume 128(5):686-698 August 4, 2016 ©2016 by American Society of Hematology

2. Overview of driver gene mutations identified by targeted sequencing in 664 AML patients. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

3. Analysis of variant allele frequencies (VAFs) of different driver gene mutations. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

4. Associations between driver gene mutations, cytogenetics, and patient characteristics. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

5. Subgroups of AML patients defined by mutually exclusive genetic alterations. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

6. Survival of patients with MRC intermediate-risk cytogenetics according to age group and DNMT3A and NPM1 mutation status. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

7. Survival of patients with MRC intermediate-risk cytogenetics according to the combined NPM1 and FLT3-ITD mutations status and DNMT3A and RUNX1 mutations. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology

8. Survival of patients with MRC adverse-risk cytogenetics according to TP53 mutation status. Klaus H. Metzeler et al. Blood 2016;128:686-698 ©2016 by American Society of Hematology